A few days ago the US National Cancer Institute (NCI) released initial results from the large-scale lung cancer screening trial; the National Lung Screening Trial (NLST), which demonstrated a 20% reduction in lung cancer mortality. This result will certainly lead to a significant change in clinical practice (see below).
IASLC is in this Newsletter announcing IASLC Fellowship Award, Young Investigators Award and the IASLC/Prevent Cancer Foundation Award. The announcement is translated into Chinese and Japanese and we encourage the Chinese and Japanese members to apply.
The IASLC has received many good recommendations for new IASLC Board of Directors and the ballot will be sent early April 2011.
For the IASLC membership fee 2011 we have introduced the electronic payment system – PayPal – and payments can be made via the website www.iaslc.org
The IASLC has hired 2 new employees – Director of Memberships and Director of Communications. They will both start November 15 and the will be presented in the next Newsletter.
As previously announced November is the lung cancer awareness month and IASLC encourages all the members in different regions to create awareness activities.
Fred R. Hirsch, MD, PhD
Lung cancer screening trial results show mortality benefit with low-dose CT:
Twenty percent fewer lung cancer deaths seen among those who were screened with low-dose spiral CT than with chest X-ray
The National Cancer Institute (NCI) has released initial results from a large-scale test of screening methods to reduce deaths from lung cancer by detecting cancers at relatively early stages.
The National Lung Screening Trial (NLST), a randomized national trial involving more than 53,000 current and former heavy smokers ages 55 to 74, compared the effects of two screening procedures for lung cancer -- low-dose helical computed tomography (CT) and standard chest X-ray -- on lung cancer mortality and found 20 percent fewer lung cancer deaths among trial participants screened with low-dose helical CT. The NLST was sponsored by NCI, a part of the National Institutes of Health, and conducted by the American College of Radiology Imaging Network (ACRIN) and the Lung Screening Study group. A paper describing the design and protocol of the NLST, “The National Lung Screening Trial: Overview and Study Design” by the NLST research team, was published yesterday by the journal Radiology and is openly available at http://radiology.rsna.org/cgi/content/abstract/radiol.10091808.
“This large and well-designed study used rigorous scientific methods to test ways to prevent death from lung cancer by screening patients at especially high risk,” said Harold Varmus, M.D., NCI Director. “Lung cancer is the leading cause of cancer mortality in the U.S. and throughout the world, so a validated approach that can reduce lung cancer mortality by even 20 percent has the potential to spare very significant numbers of people from the ravages of this disease. But these findings should in no way distract us from continued efforts to curtail the use of tobacco, which will remain the major causative factor for lung cancer and several other diseases.”
Starting in August 2002, the NLST enrolled about 53,500 men and women at 33 trial sites nationwide over a 20 month period. Participants were required to have a smoking history of at least 30 pack-years and were either current or former smokers without signs, symptoms, or history of lung cancer. Pack-years are
calculated by multiplying the average number of packs of cigarettes smoked per day by the number of years a person has smoked.
The trial participants received their screening tests at enrollment and at the end of their first and second years on the trial. The participants were then followed for up to another five years; all deaths were documented, with special attention given to the verification of lung cancer as a cause of death. At the time the DSMB held its final meeting on October 20, 2010, a total of 354 deaths from lung cancer had occurred among participants in the CT arm of the study, whereas a significantly larger 442 lung cancer deaths had occurred among those in the chest X-ray group. The DSMB concluded that this 20.3 percent reduction in lung cancer mortality met the standard for statistical significance and recommended ending the study.
For a Fact Sheet on the NLST, please go to http://www.cancer.gov/newscenter/pressreleases/NLSTFastFacts.
For more information on lung cancer and screening, please go to http://www.cancer.gov/cancertopics/types/lung.
“The National Lung Screening Trial: Overview and Study Design" has been published by Radiology. This paper is openly available at http://radiology.rsna.org/cgi/content/abstract/radiol.10091808.
IASLC Lung Cancer Fellowship Award - 2 years duration
IASLC Young Investigators Award - 2 years duration
IASLC/PCF Prevent Cancer Foundation Fellowship Award - 2 years duration
The IASLC is proud to announce the annual IASLC Fellowship and Young Investigators Programs.
Overall, there are 3 or more awards for two years each and at least one applicant from each region (North America, Europe and Rest of the World) will be funded. There are awards in prevention and translational lung cancer research that are jointly sponsored with the Prevent Cancer Foundation, (PCF), through educational grants from Eli Lilly. There are unrestricted awards in any field of lung cancer research supported by educational grants from Amgen, Genentech, OSI, Eli Lilly, the IASLC and other sponsors.
This year at least 3 new unrestricted awards of $40,000 each year for 2 years are available for competition.
We are now requesting application for these Fellowships and Young Investigator awards to be awarded in 2011 - 2012. The goal is to reward scientific excellence and to encourage innovative investigations in the field of lung cancer prevention research and translational research with a potential impact on the management of lung cancer. The applications will be evaluated by a Scientific Review Panel; the deadline for submission of the application is January 10, 2011. A decision on applications will be reached by March 2010.
Application forms can be found at the website: www.iaslc.org
Please e-mail you application to: pia.Hirsch@ucdenver.edu latest January 10, 2011.
ASLC Staging Manual:
The IASLC Staging Manual and Handbook in Thoracic Oncologic has now surpassed 35,000 copies sold worldwide. In addition, the Staging Posters and Reference Cards continue to be popular reference aids of the 7th edition staging system for practitioners and tumor boards. IASLC members can continue to order these publications and products at special member pricing (www.iaslcpubs.org; contact email@example.com for further information).
In addition, translations of these publications have been completed or are in process in multiple languages: Chinese, Italian, Japanese, Polish, and Turkish. Discussions about future translations in Spanish, Arabic, and Russian are ongoing.
The new IASLC Staging Manual has been published in different formats. Several years of work from the IASLC Staging Committee and particularly the chair Dr. Peter Goldstraw, has resulted in a formal staging manual. The book and the “pocket-cards” can be ordered at www.iaslc.org
JTO Mobile options
JTO is available for your iPhone, Blackberry, or Android phone, in a view designed for easy reading on a small screen. Type jto.org into your phone’s browser to access the site. You can view current issue table of contents, most viewed articles, most emailed articles, or search across issues. If you have created a user name and password on the desktop version of JTO.org, you can use that same log in information to view full text articles, complete with illustrations.
IASLC Textbook – Editor in Chief:
Harvey I. Pass, MD
Lung Cancer Book from Lippincott: The Fourth Edition of Principles and Practice of Lung Cancer, edited by Harvey I. Pass, MD et al is now available. For more information about the 1040 page book, with 330 illustrations (ISBN-10:0-7817-7365-2) or www.lww.com/product/?978-0-7817-7365-2.
James R Jett MD has joined the faculty of National Jewish Health, Department of Medicine and section of Oncology, in Denver, Colorado. He is joining Dr Jeffrey Kern, Chief of Oncology, who started the program in 2009. Dr Jett is Professor of Medicine with responsibilities in both patient care and clinical and translational research, with an emphasis on screening and early detection of lung cancer. " I am delighted about this wonderful opportunity to work with the outstanding scientists and clinicians at National Jewish Health and the University of Colorado. This is an opportunity of a lifetime." Dr Jett will continue his responsibilities as Editor-in-Chief of the Journal of Thoracic Oncology
IASLC Welcomes 63 new members from August – October 2010
Mariana Laura Abal
Mary Elizabeth Finan
Eun Kyung Choi
Si Yeol Song
Ho Kee Yum
Bernadette R. Asuncion
Jan von der Thusen
Luis M.M. Barrera
Francisco J. Ochoa-Carrillo
Chantal Van der Graaf
John Callison, Jr.
Elias Ramon Adle Acosta
Upcoming IASLC Workshops/Meetings 2010 - 2011
November 10-14, 2010 4th National Lung Cancer Congress Location: Antalya, Turkey Email: firstname.lastname@example.org
December 2-4, 2010 4th Asia Pacific Lung Cancer Conference (APLCC 2010) Location: Seoul, South Korea Email: email@example.com
December 2-4, 2010 12th Central European Lung Cancer Conference (CELCC) Location: Budapest, Hungary Email: firstname.lastname@example.org Website: www.celcc2010-budapest.hu/ On-line registration and on-line abstract submission possibilities are already open! Abstract submission deadline: via Internet September 30, 2010 Early registration: September 30, 2010
December 9-11, 2010 ASCO/ASTRO/IASLC/University of Chicago Multidisciplinary Symposium in Thoracic Oncology Location: Chicago, IL Email: email@example.com To view the symposium Web site visit: www.thoracicsymposium.org HURRY! Submit Your Abstracts! Only 2 weeks remain before July 14th deadline! Click here for more information.
February 17, 2011 Tehran, Iran Symposium Update on diagnosis and treatment of non-small cell lung cancer Location: Tehran, Iran Email: firstname.lastname@example.org
July 3-7, 2011 14th World Conference on Lung Cancer Location: Amsterdam, The Netherlands Click here for more information
Become a Member
Join the only international association solely dedicated to lung cancer research and treatment.